Drugs & Treatments

Phase II Study of Nitric Oxide for Men with Increasing PSAs After Primary Treatment for Prostate Cancer

Biochemical recurrence of prostate cancer after primary therapy (PSA only) remains a significant problem. Deciding on the best treatment options for men who have failed primary therapy without documented evidence of metastatic disease remains limited and controversial. Androgen deprivation therapy (ADT), the usual next step for biochemical recurrence does prolong the time to further disease [...]

By Malecare|2017-10-19T10:53:45-04:00July 26th, 2010|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Research, Technology, Uncategorized, Understanding APC|7 Comments

Can Our Society Find Its Way To An Honest Dialogue About The Price Of A Human Life?

What is the real cost of approved treatments for advanced prostate cancer and how much we should spend? These questions are rippling through the prostate cancer community and the general population. […]

By Malecare|2017-10-19T10:53:46-04:00July 23rd, 2010|Advanced Prostate Cancer, Advocacy, Cabazitaxel, Chemo Therapy, Drugs & Treatments, General Information, How We Live, Politics of Cancer, Uncategorized, Understanding APC|1 Comment

Docetaxel (Chemotherapy) Re-Treatment – Can It Work Again?

A group of researchers from the Dipartimento di Endocrinologia ed Oncologia Clinica e Molecolare, Università Federico II, Napoli, Italy wanted to know if retreatment with docetaxel could be tolerated and have a positive effect in men with castration-resistant prostate cancer (CRPC) who have already failed chemotherapy. The researchers evaluated 45 men who had initially responded [...]

By Malecare|2017-10-19T10:53:46-04:00July 21st, 2010|Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Drugs & Treatments, Research, Uncategorized, Understanding APC|0 Comments

Sanofi-aventis Announces that Jevtana® (cabazitaxel) Injection Is Now Available in the U.S.

Sanofi-aventis, the pharmaceutical company that makes taxotere and the newly approved drug, Jevtana (cabazitaxel) yesterday announced that their newly approved treatment for men with metastatic hormone-refractory prostate cancer (mHRPC) who have been previously treated with a docetaxel-based treatment regimen and failed is finally available for distribution in the United States. Around one month ago, Jevtana [...]

By Malecare|2017-10-19T10:53:46-04:00July 20th, 2010|Advanced Prostate Cancer, Cabazitaxel, Chemo Therapy, Chemo Therapy Failure, Drugs & Treatments, Financial, Uncategorized, Understanding APC|18 Comments

An Important Fact from the 2010 AUA Meeting

Findings from the Prostate, Lung, Colorectal and Ovarian (PLCO) screening trial indicate that the strongest predictors of prostate cancer-specific mortality include Gleason 7, body mass index >30, African-American race, PSA level, stage, and high co-morbidity score. Understanding how non-tumor factors affect prostate cancer-specific mortality will help identify those men who may benefit from screening and [...]

By Malecare|2010-07-14T14:41:43-04:00July 14th, 2010|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Uncategorized, Understanding APC|0 Comments

Finasteride Extends PSA Doubling Time & Reduces the Rate of PSA Increase

Finasteride, which remains a controversial drug in the treatment of men with advanced prostate cancer, prolongs the time of off-treatment in men with advanced prostate cancer when they are using intermittent androgen suppression therapy (IAD). One of the questions not yet understood is whether this results from a true increase in prostate-specific antigen (PSA) doubling [...]

By Malecare|2020-02-04T11:51:54-05:00July 12th, 2010|Advanced Prostate Cancer, Drugs & Treatments, General Information, Hormone Therapy, Research, Uncategorized, Understanding APC|0 Comments

An Editorial – What Has Caused the Recent Review of Provenge by the CMS

There has been a lot of questions raised about why the Centers for Medicaid and Medicare Services (CMS) has out of the clear blue, launched a review of Provenge, a review that could ultimately make Provenge unavailable to men on Medicare and Medicaid (see the post:Medicare Funding for Provenge, We Urgently Need Your HELP). There [...]

By Malecare|2017-10-19T10:53:47-04:00July 9th, 2010|Advanced Prostate Cancer, Advocacy, Drugs & Treatments, Financial, General Information, How We Live, Politics of Cancer, Provenge, Uncategorized, Understanding APC, vaccines|0 Comments

The Long-Term Survival of Patients with Metastatic Prostate Cancer

Mike Scott who writes the THE “NEW” PROSTATE CANCER INFOLINK today published an excellent summary/discussion about survival time for men with metastatic prostate cancer. He presents a synopsis about anticipated survival going back to the late 1980s and brings the conversation up to our current condition. He reminds us that our next big step will [...]

By Malecare|2020-02-04T10:35:42-05:00July 8th, 2010|Advanced Prostate Cancer, Cabazitaxel, Chemo Therapy, Drugs & Treatments, General Information, Hormone Therapy, How We Live, MDV3100, Politics of Cancer, Prostate Ponderings, Provenge, Research, Uncategorized, Understanding APC|9 Comments

Salvage Radiotherapy (SRT) After High-Intensity Focused Ultrasound (HIFU) for Recurrent Localized Prostate Cancer

The use of high-intensity focused ultrasound (HIFU) for the primary treatment of prostate cancer will probably become more common in the very near future. HIFU has been used for many years in Europe and Mexico and has recently been in clinical trials in the United States. HIFU has been a successful method of prostate cancer [...]

By Malecare|2017-10-19T10:53:48-04:00July 7th, 2010|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, HIFU, On The Horizon, Radiotherapy, Uncategorized, Understanding APC|0 Comments

Phase II trial Combining Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Men with Metastatic Castration-Resistant Prostate Cancer

Dr. Yang-Min Ning and collaborators reported, in the April 20, 2010 issue of the Journal of Clinical Oncology, a Phase II trial which combined chemotherapy (docetaxel) with an anti-angiogenesis drug for men with castration-resistant prostate cancer (CRPC). The data suggests that such a combination is more effective than chemotherapy alone. […]

By Malecare|2017-10-19T10:53:48-04:00July 6th, 2010|Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, Research, thalidomide, Uncategorized, Understanding APC|0 Comments